Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa Study of HL217 Eye Drops in Exudative Age-Related Macular Degeneration
2019-000642-35Phase 2Terminated
- Sponsor
- Hanlim Pharm
- Start
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of KR-31831 in age-related macular degeneration (AMD) (2 arms), sponsored by Hanlim Pharm. Started Feb 2019; status: terminated.
02
Drugs
KR-31831
03
Conditions
age-related macular degeneration (AMD)
Beyond the preview
Go deeper on 2019-000642-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000642-35.